ema401造句

• EMA401 does not accumulate in the blood at presently administered doses.
• There was no evidence of any serious side effects caused by EMA401.
• No serious adverse effects have been determined that directly associates with EMA401.
• The mechanism of why EMA401 may increases frequency of headaches is unknown.
• EMA401 has been administered orally at a standardized dose of 100 mg twice daily.
• Phase I clinical trial also indicated EMA401 dose of up to 400 mg to be safe.
• EMA401 does not cross the blood-brain barrier, therefore has little effect on the central nervous system.
• Slightly higher frequency of complaints such as pharyngitis, headaches and allergic dermatitis are reported by individuals taking EMA401.
• EMA401 dose of up to 400 mg was tested in healthy male adults without any presentation of complications indicating safety issues.
• Headache frequency was higher in patients receiving EMA401 over placebo in both phase 1 and phase 2 clinical trials for EMA401.
• Headache frequency was higher in patients receiving EMA401 over placebo in both phase 1 and phase 2 clinical trials for EMA401.
• EMA401 has a t of 6 hours on day 1 of drug intake and a t of 12 hours on day 7 of drug intake.
• A nonrandomized Phase 2 study of EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy was approved and is currently underway.
• EMA401 is more effective and has virtually no central nervous system side effects in comparison to current drugs for pain relief, such as Neurotin and Lyrica.
• EMA401 target proteins, angiotensin II type 2 receptors, are extremely important for nociception within the peripheral nervous system and less so for nociception within other functional systems.
• Total plasma concentration of EMA401 is consistent over 28 days . A steady state of minimum drug plasma concentration is reached by the 8th day of being on the drug.
• "' EMA401 "'is a new drug under development for the treatment of Analgesic treatments currently available for pain disorders are unsuited for severe chronic neuropathic pains.
• EMA401 is the first drug on the market that targets angiotensin II type 2 receptors ( ATR ) with high affinity but has a low affinity for angiotensin II type 1 receptors.
• Animal studies, five Phase I clinical trials, unpublished data at Spinifex Pharmaceuticals, implicated a dose range of 10 50 mg per day of EMA401 to be effective on human beings.
• EMA401 reaches a maximum plasma concentration of 1000 ug / L one-hour after administration of 100 mg of EMA401 in both men and women, as observed in a phase II trial.